Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re Pfizer Inc. Shareholder Derivative Litigation
Case Number:
1:09-cv-07822
Court:
Nature of Suit:
Multi Party Litigation:
Derivative Litigation
Judge:
Firms
- Bernstein Litowitz
- Brower Piven
- Cadwalader Wickersham
- Davis Polk
- DLA Piper
- Greenberg Traurig
- Kirby McInerney
- Law Offices of Curtis V. Trinko
- Orrick Herrington
- Pomerantz LLP
- Robbins Geller
Companies
Government Agencies
Sectors & Industries:
-
February 08, 2011
Attorneys Seek $22M In Fees For Pfizer Settlement
The plaintiffs' counsel in a shareholder class action against Pfizer Inc. executives over an allegedly fraudulent marketing campaign have asked a judge to sanction $22 million in attorneys' fees as part of the final approval of a $75 million settlement.
-
December 15, 2010
Pfizer Wins OK For $75M Deal In Shareholder Suits
A federal judge has given an initial blessing to Pfizer Inc.'s proposed $75 million settlement to end a slew of derivative suits lodged against the drugmaker's executives over a marketing campaign that resulted in $2.3 billion in claims.
-
October 15, 2009
Skandia Joins Race For Lead Status In Pfizer Case
Skandia Life Insurance Co. Ltd. has become the latest party to request lead plaintiff status in a consolidated derivative lawsuit accusing Pfizer Inc. executives of harming the company by promoting prescription drugs for unapproved off-label uses.
-
October 09, 2009
Investors Compete To Lead Pfizer Derivative Suit
Institutional investor Amalgamated Bank is competing with an individual shareholder over who will lead a consolidated derivative lawsuit alleging that Pfizer Inc.'s executives harmed the company by promoting prescription drugs for unapproved, off-label uses.
-
September 11, 2009
Derivative Suit Filed In Wake Of Record Pfizer Payout
The entire board of directors at Pfizer Inc. and certain executives have been smacked with a shareholder derivative lawsuit alleging they harmed the company by promoting prescription drugs for unapproved, off-label uses.